Examples of using Chmp in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
The CHMP appointed Dr.
What are the conclusions of the CHMP?
The CHMP endorsed following text.
Responses to the Remaining Issues and CHMP assessment.
For section 4.8, the CHMP assessed and harmonised the wording.
People also translate
The CHMP noted that five N. meningitidis bacterial groups(A, B, C, W135 and Y) are responsible for invasive disease, and that Menveo provides broader protection than other available vaccines.
Based upon the data that have becomeavailable since the granting of the initial Marketing Authorisation, the CHMP considers that the benefit-risk balance of Trobalt remains positive, but considers that its safety profile is to be closely monitored for the following reasons.
The CHMP noted that in children the immune system's response to Prevenar 13 was comparable to that of Prevenar, which is already authorised for the protection of children against S. pneumoniae in the EU.
On the basis of the scientificconclusions for para-aminosalicylic acid(centrally authorised product) the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing para- aminosalicylic acid(centrally authorised product) is unchanged subject to the proposed changes to the product information.
The CHMP closely monitors reports of potential safety concerns across Europe and, when necessary, makes recommendations to the European Commission regarding changes to a medicine's marketing authorisation, or its suspension/withdrawal from the market.
The Summary of Products Characteristic, labelling and package leaflet proposed by the applicant has been assessed based on the documentation submitted andthe scientific discussion within the Committee. the CHMP has recommended the granting of the Marketing Authorisations for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Lansoprazol ratiopharm and associated names see Annex I.
The hoody Varsity Chmp is in warm plush cotton and is ideal to match with a pant suit to go to the gym or to return home from the gym.
The CHMP has recommended the amendment of the Marketing Authorisations for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Zyrtec and associated names see Annex I.
On the basis of the scientific conclusions for liraglutide the CHMP is of the opinion that the benefit risk balance of the medicinal products containing liraglutide is unchanged subject to the proposed changes to the product information.
The CHMP was concerned that only a modest benefit of NutropinAq in severe idiopathic short stature had been demonstrated, with an average gain in final adult height of around 6 to 7 cm in the main study.
On the basis of the scientific conclusions for Vipidia, the CHMP is of the opinion that the benefit- risk balance of the medicinal product containing the active substance alogliptin is favourable subject to the proposed changes to the product information.
The CHMP also considered the fact that Triumeq can be taken with or without food as an additional advantage compared with other similar medicines which have to be taken strictly either with food or on an empty stomach.
On the basis of the scientific conclusions for apremilast the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing apremilast is unchanged subject to the proposed changes to the product information.
The CHMP has recommended the granting of the Marketing Authorisation(s) for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Doxazosin“ Arrow” 4 mg prolonged release tablets and associated names see Annex I.
For the indication in Manic episodes associated with Bipolar Disorders, the CHMP assessed the safety and efficacy of the proposed 2 mg and 3 mg starting doses and noted that no comparisons on the change in efficacy measurements in the first days of treatment were made.
CHMP was of the opinion that the bioequivalence was sufficiently established after single dose administration in two different bioequivalence studies(study 463/ 04 and 1995/ 04-05) and after multiple dose administration(study 5208/ 02-3) according to the CHMP guidelines.
On the basis of the scientificconclusions for gimeracil/ oteracil monopotassium/ tegafur the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing gimeracil/ oteracil monopotassium/ tegafur is unchanged subject to the proposed changes to the product information.
The CHMP has recommended the amendment of the Summaries of Product Characteristics and the granting of the Marketing Authorisations for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Rapinyl and associated names see Annex I.
In addition to the list of follow-up measures discussed andrequested by the CMDh, the CHMP requested the following follow-up measures to be submitted to the National Competent Authorities and to be assessed under the co-ordination of the RMS:• To perform a post-marketing study to confirm the safety and efficacy of Xeomin after repeated injections up to 6 injection sessions.
Ibuprofen, naproxen, denuded and acomplia sag chmp or desulfated interventions, scaly do not understan in hyperketonemia(goldenberg, 2004, o'malley, 2000), although successful addiction to recolonization buckhardt, 2005.
After a careful review of the data submitted the CHMP considered that the therapeutic indication of ciprofloxacin in prophylaxis of invasive infections due to Neisseria meningitidis in adults was well substantiated by publications and corresponded to the current practice.
The Committee for Medicinal Products for Human Use(CHMP) concluded that IONSYS offers potential benefits compared to systems where the pain relief is given via a vein: it is non-invasive, needle-free and pre-programmed, and it can be activated by the patient.
For adolescents with type 2 diabetes, the CHMP concluded that although safety and effectiveness had only been shown for type 1 diabetes, the results of studies carried out in adolescents with type 1 and other studies in adults with type 2 diabetes could be applied to adolescents with type 2.
Based on the review of the data and on the Applicant responses to list of outstanding issues andto the remaining issues, the CHMP considered the benefit/ risk ratio of Rapinyl to be positive and the application for Rapinyl sublingual tablet 50, 100, 200, 300, 400, 600 and 800 μ g to be approvable, provided that the Applicant implements the amendments made to the text of the Product Information and fulfills the conditions to the Marketing Authorisation as described in Annex IV.